Metsera

Pfizer has won the bidding war against Novo Nordisk to acquire obesity-drug biotech Metsera. The pharma giant upped its offer, valuing the startup at up to around $10 …

Top of the morning to you, and a fine one it is. Despite howling winds lashing the Pharmalot campus, the skies are clear and sunny, and the official …

The Federal Trade Commission has raised concerns about Novo Nordisk’s attempt to outbid Pfizer to acquire obesity startup Metsera, the latest complication in a dramatic bidding war between …

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We’re hosting a virtual event …

Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer intensifies. This is up from the $8.5bn that …

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — Novo Nordisk’s new CEO dismissed on Wednesday …

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We’ve got all the latest on the …

Pfizer said Friday it’s suing Novo Nordisk and obesity biotech Metsera, a day after Novo set off a bidding war against Pfizer to acquire Metsera. A month ago, …